SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vector1 who wrote (111)4/18/1998 12:32:00 PM
From: scaram(o)uche of 4974
 
V1:

I've followed the development of AQLA's saponin derivative adjuvant since it was in early development. Rick Coughlin, who did much of the early work, was hired from Centocor as Section Manager, Immunology at what was then Cambridge Biotech. Don't know if he's still there, but, if so, he'd make a good contact.

Always thought that the adjuvant was better than those in development at CYTR or RIBI, but, after the bankruptcy, I never thought that they'd bounce back so successfully. The 10-K must be a nightmare to get through.

Thanks!

Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News